The Swiss medicines regulator Swissmedic has for the first time authorised a drug (Donanemab) that can slow down the progression of Alzheimer's disease. +Get the most important news from Switzerland in your inbox Swissmedic rates the benefits of the active substance higher than possible side effects. In a joint press release with Swiss Memory Clinics, Alzheimer Switzerland welcomed the authorisation. + Swiss regulators weigh hope and hype with new Alzheimer’s drugs The antibody Donanemab, developed by Eli Lilly under the trade name Kisunla, reduces protein deposits in the brain. It is intended for patients in the early stages of the disease and is designed to delay cognitive decline. However, the treatment also has potential risks such as brain swelling or bleeding and requires careful monitoring. It is still unclear whether the costs will be covered by health insurance companies. Adapted from German by AI/mga How we work We select the most relevant news for an international ...
